Johnson & Johnson (JNJ) Current Assets (2009 - 2026)
Johnson & Johnson (JNJ) posted Current Assets of $59.8 billion for Q2 2026, up 1.02% sequentially from $59.2 billion in Q1 2026, and up 9.68% YoY from $54.5 billion in Q2 2025.
Johnson & Johnson (JNJ) Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Current Assets for 18 years, with the latest figure at $59.8 billion in Q2 2026.
- Quarterly Current Assets rose 9.68% year-over-year to $59.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $59.8 billion (up 9.68% YoY) and the FY2025 annual result came in at $55.6 billion, changed 0.48% from the prior year.
- Current Assets climbed to $59.8 billion in Q2 2026 per JNJ's latest filing, from $59.2 billion in the prior quarter.
- Over five years, Current Assets peaked at $71.6 billion in Q1 2025 and troughed at $53.2 billion in Q3 2024.
- A 5-year average of $58.8 billion and a median of $57.8 billion in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets fell 17.68% in 2023, then climbed 25.52% in 2025.
- Over 5 years, Current Assets stood at $65.2 billion in 2022, then decreased by 18.0% to $53.5 billion in 2023, then gained by 4.48% to $55.9 billion in 2024, then decreased by 0.48% to $55.6 billion in 2025, then climbed by 7.46% to $59.8 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $59.8 billion, $59.2 billion, and $55.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 59.77 Bn |
| Mar 29, 2026 | 59.17 Bn |
| Dec 28, 2025 | 55.62 Bn |
| Sep 28, 2025 | 54.61 Bn |
| Jun 29, 2025 | 54.50 Bn |
| Mar 30, 2025 | 71.55 Bn |
| Dec 29, 2024 | 55.89 Bn |
| Sep 29, 2024 | 53.25 Bn |
| Jun 30, 2024 | 57.82 Bn |
| Mar 31, 2024 | 57.00 Bn |
| Dec 31, 2023 | 53.50 Bn |
| Oct 1, 2023 | 53.70 Bn |
| Jul 2, 2023 | 60.57 Bn |
| Apr 2, 2023 | 64.39 Bn |
| Jan 1, 2023 | 55.29 Bn |
| Oct 2, 2022 | 65.24 Bn |
| Jul 3, 2022 | 63.85 Bn |
| Apr 3, 2022 | 60.42 Bn |
| Jan 2, 2022 | 60.98 Bn |
| Oct 3, 2021 | 59.89 Bn |